Chromocell Therapeutics (CHRO) Competitors $2.66 +0.76 (+40.00%) Closing price 04:00 PM EasternExtended Trading$2.62 -0.04 (-1.50%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CHRO vs. NXTC, CARA, TRAW, PULM, COCP, TENX, XCUR, ATHA, GOVX, and MIRAShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include NextCure (NXTC), Cara Therapeutics (CARA), Traws Pharma (TRAW), Pulmatrix (PULM), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. NextCure Cara Therapeutics Traws Pharma Pulmatrix Cocrystal Pharma Tenax Therapeutics Exicure Athira Pharma GeoVax Labs MIRA Pharmaceuticals NextCure (NASDAQ:NXTC) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Which has higher earnings and valuation, NXTC or CHRO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$2.09-0.39Chromocell TherapeuticsN/AN/A-$7.38MN/AN/A Does the media favor NXTC or CHRO? In the previous week, Chromocell Therapeutics' average media sentiment score of 0.00 beat NextCure's score of -0.06 indicating that Chromocell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NextCure Neutral Chromocell Therapeutics Neutral Is NXTC or CHRO more profitable? Chromocell Therapeutics' return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% Chromocell Therapeutics N/A N/A -453.90% Does the MarketBeat Community believe in NXTC or CHRO? NextCure received 79 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 64.52% of users gave NextCure an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8064.52% Underperform Votes4435.48% Chromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Do analysts recommend NXTC or CHRO? NextCure currently has a consensus target price of $4.00, suggesting a potential upside of 394.44%. Given NextCure's higher possible upside, equities research analysts plainly believe NextCure is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in NXTC or CHRO? 42.7% of NextCure shares are held by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryChromocell Therapeutics beats NextCure on 6 of the 10 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$18.94M$2.99B$5.37B$19.99BDividend YieldN/A1.89%5.37%3.61%P/E RatioN/A44.7186.7641.58Price / SalesN/A292.961,278.6017.38Price / CashN/A189.5236.6017.54Price / Book-1.823.974.925.82Net Income-$7.38M-$40.99M$117.96M$1.01B7 Day Performance219.21%2.73%2.19%2.97%1 Month Performance366.98%0.10%3.21%5.47%1 Year PerformanceN/A-0.75%26.71%19.77% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$2.66+40.0%N/AN/A$16.04MN/A0.004Gap UpHigh Trading VolumeNXTCNextCure4.2775 of 5 stars$0.78-2.3%$4.00+412.5%-30.2%$21.86MN/A-0.3790CARACara Therapeutics4.0328 of 5 stars$4.77+0.4%$27.84+483.6%-31.4%$21.79M$8.69M-2.7380TRAWTraws Pharma0.4959 of 5 stars$7.20-10.7%N/AN/A$21.79M$226,000.00-0.0517Gap DownPULMPulmatrix0.9772 of 5 stars$5.96-0.8%N/A+245.2%$21.77M$10.01M-2.2620Positive NewsCOCPCocrystal Pharma2.5895 of 5 stars$2.08-5.9%$7.00+236.5%+22.2%$21.16MN/A-1.1210Positive NewsGap DownTENXTenax Therapeutics2.0236 of 5 stars$6.08-2.6%$16.00+163.2%-35.1%$20.73MN/A0.009XCURExicure1.7233 of 5 stars$7.88-16.7%N/A+1,578.3%$20.54M$500,000.00-3.8150ATHAAthira Pharma3.609 of 5 stars$0.53-6.8%$13.83+2,526.9%-81.6%$20.36MN/A-0.1840Gap UpGOVXGeoVax Labs3.3121 of 5 stars$2.10-5.8%$14.20+576.2%-50.7%$19.82M$3.09M0.0010MIRAMIRA Pharmaceuticals2.7189 of 5 stars$1.18-6.3%$14.00+1,085.6%+45.7%$19.56MN/A-2.112 Related Companies and Tools Related Companies NextCure Competitors Cara Therapeutics Competitors Traws Pharma Competitors Pulmatrix Competitors Cocrystal Pharma Competitors Tenax Therapeutics Competitors Exicure Competitors Athira Pharma Competitors GeoVax Labs Competitors MIRA Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CHRO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
